MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.esmoop.2024.103658

Медицинская библиотека · ESMO open · 2024

Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study.

Trapani D, Scalia R, Giordano E, Castellano G, Doi G, Gaeta A, Pellizzari G, Carnevale Schianca A, Katrini J, D'Ambrosio S, Santoro C, Guidi L, Valenza C, Belli C, Gandini S, Russo A, Curigliano G

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Interstitial lung disease (ILD) encompasses a heterogeneous group of disorders sharing pathophysiological inflammatory mechanisms, leading to parenchymal distortions. The prevalence of ILD with new cancer drugs is underreported: the identification of potential determinants is priority.

MATERIALS AND

METHODS

ILDE is a retrospective study aimed at describing the clinical course and potential determinants of ILD in patients receiving experimental treatments.

RESULTS

We identified 226 eligible patients, of whom 5.3% (n = 12) had ILD. In five patients, the diagnosis was radiological, while seven patients had initial cough, dyspnea, fatigue or fever. ILD was graded as grade 1 (G1) in four, G2 in five and G3 in three patients. The first occurrence of ILD resolved completely in 50% of patients (n = 6/12). No patient had fatal ILD. Eight patients (66.7%) resumed the treatment after the first episode of ILD, while four patients (33.3%) had to discontinue the therapy. Five out of six patients had resolved the first ILD episode and then resumed treatment, experiencing a second ILD episode (n = 5/6; 83.3%). The second ILD event was G1 in three patients and G2 in two patients, resulting in three patients who eventually discontinued the treatment (n = 3/5; 60%). Correlation analysis showed a higher risk of ILD in older patients (P = 0.051), those who had received previous chest radiation therapy (P = 0.047) or those receiving antibody-drug conjugates (P = 0.006). In a survival analysis adjusted for immortal time bias, ILD was not independently prognostic (hazard ratio 0.50, 95% confidence interval 0.23-1.09, P = 0.082).

CONCLUSIONS

In ILDE, patients experiencing ILD had generally good outcomes, and many could resume the cancer treatments. Implementing best practices to prompt diagnosis and management of ILD is critical to treat a potentially severe adverse effect of new drugs, while not affecting patients' outcomes. Research efforts to identify risk factors is warranted, to implement risk-based monitoring schedules and develop ad hoc strategies to improve the cure rates of ILD.

Для цитирования: Trapani D, Scalia R, Giordano E, Castellano G, Doi G, Gaeta A, Pellizzari G, Carnevale Schianca A, Katrini J, D'Ambrosio S, Santoro C, Guidi L, Valenza C, Belli C, Gandini S, Russo A, Curigliano G. Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study.. ESMO open. 2024. DOI: 10.1016/j.esmoop.2024.103658.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.